Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 3 4Phase 2 3

Status

Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2NET 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 2Neuroendocrine Tumors 1Neoplasms 1

Interventions

pembrolizumab 514Specimen Handling 382Carboplatin 372Magnetic Resonance Spectroscopy 333Cisplatin 327Nivolumab 303Cyclophosphamide 295Radiotherapy 255Paclitaxel 252Biopsy 235Gemcitabine 231Bevacizumab 212Dexamethasone 167durvalumab 162Oxaliplatin 160Capecitabine 155Rituximab 152Fluorouracil 148venetoclax 143Docetaxel 143atezolizumab 141Drug Therapy 140Etoposide 139Doxorubicin 131Ipilimumab 126Radiosurgery 118Prednisone 117Lenalidomide 117Leucovorin 111fludarabine 109

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × AMG 757 × 1 year × Clear all
NCT06502977 2026-04-15

DeLLphi-307

Amgen

Phase 2 Active not recruiting
32 enrolled 9 charts
EndocrineNET

Neoplasms, Neuroendocrine Tumors

NCT06745323 2026-03-03

DeLLphi-309

Amgen

Phase 2 Active not recruiting
252 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT07423585 2026-02-20

Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
39 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡